Comprehensive Biologics Testing for Monoclonal Antibodies (mAbs)
Monoclonal antibodies (mAbs) are complex biologics used in targeted therapies for cancer, autoimmune disorders, and neurodegenerative diseases. Their development requires rigorous CMC testing, biosafety assessments, and regulatory compliance at every stage—from IND-enabling studies to clinical manufacturing and release.
With over 25 years of expertise that includes mAb characterization, CHO cell line characterization, and mAb and recombinant testing, Charles River provides end-to-end mAb testing services designed to overcome development challenges and streamline your path to market. We offer monoclonal antibody testing services in a variety of species, and projects can either be customized to client-specific requirements or follow Charles River standard GMP-certified protocols.
Monoclonal Antibody Testing Capabilities
- Cell Banking Services
- Cell Line Characterization
- Unprocessed Bulk Testing
- Viral Clearance
- Method Development to Validation
- Bioassay and Potency Testing
- Lot Release and Stability Testing
Mastering Microbial Cell Banking & Characterization
Experts discuss cell banking and characterization, focusing on regulatory guidelines for biologics, microbial cell bank manufacturing, release testing (including phage, purity, titer, viability, and identification), and additional testing for microbial cell lines.
Watch Now
Monoclonal Antibody Testing Services
Key aspects of monoclonal antibody testing include assessing purity, potency, and stability. These tests ensure that the drug is delivered effectively, is recognized by the body, and has the correct composition for both efficacy and safety. Our support in mAb testing includes:
- Integrated CRO Services: From early characterization to stability and release testing, we are your single-source partner.
- Advanced Analytical Methods: ELISAs, cell-based assays, HPLC-MS/MS, binding and functional assays for precise potency and purity analysis.
- Rapid Timelines: Accelerate cell line characterization and clone selection with NGS-based insights.
- Risk Mitigation: Proactive screening of raw materials and adventitious agents to safeguard your manufacturing process.
- Real-Time Data Access: Our Apollo™ platform offers secure, cloud-based visibility into sample status, milestones, and documentation.
- Innovation: We are leaders both in innovation and adoption of Next Generation Sequencing (NGS), an acceptable alternative to traditional culture or animal-based testing, and offer a fast-track NGS-based cell line characterization program that releases a Master Cell bank within six weeks instead of 3-5 months with traditional test programs.
Next-level viral safety testing
Biologics are vulnerable to viral contamination, posing a risk to patient safety. This whitepaper discusses traditional detection methods and their limitations and demonstrates how validated NGS technology can enhance viral safety testing, ensuring reduced risk and expedited market access.
Read the Whitepaper
Regulatory Guidance for Monoclonal Antibody Testing
In the evolving landscape of biopharmaceutical development, adherence to rigorous testing standards is paramount. Regulatory authorities such as the FDA and EMA provide critical guidance on the evaluation of mAbs, highlighting essential aspects including comprehensive characterization, stability assessments, and stringent manufacturing controls. This framework not only ensures compliance but also reinforces the commitment to delivering safe and effective therapeutics to patients.
| Regulatory Body | Guideline | Link |
|---|---|---|
| ICH | Q6B – Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products | Q6B (1999, Step 4) [database.ich.org] |
| ICH | S6(R1) – Preclinical Safety Evaluation of Biotechnology‑Derived Pharmaceuticals | S6(R1) (2011, Step 4) [database.ich.org] |
| EMA | CHMP Guideline (2016) – Development, production, characterization and specification for monoclonal antibodies and related products | EMA CHMP Guideline (July 2016) [ema.europa.eu] |
| EMA | Immunogenicity Guideline (2012) – Assessment of immunogenicity of mAbs for in vivo clinical use | EMA Immunogenicity Guideline (May 2012) [ema.europa.eu] |
| FDA | CMC Guidance – Bispecific Antibody Development Programs (May 2021) | FDA CMC & GMP Guidances [fda.gov] |
| FDA | Monoclonal Antibodies: Streamlined Nonclinical Safety Studies – Draft Guidance (Dec 2025) | FDA Draft Guidance (Dec 2025) [fda.gov] |
| WHO | Guidelines for the Production and Quality Control of Monoclonal Antibodies (2022) | WHO Guidelines (April 2022) [who.int] |
| WHO | Nonclinical & Clinical Evaluation of mAbs for Infectious Diseases (2023) | WHO ECBS Guide (March 2023) [cdn.who.int] |
| USP | Monoclonal Antibody Analytical Guide & Reference Standards | USP mAb Analytical Guide [usp.org] |
| EU | EudraLex Volume 3 – GMP requirements for mAb production (EMA CHMP guideline incorporated) | EMA CHMP Guideline (2016) [ema.europa.eu] |
Charles River commends the FDA's efforts to enhance animal welfare in mAb development and supports their initiative to streamline drug development, reduce costs, and foster innovation while ensuring the ethical use of animals in research. Committed to the 3Rs—Replacement, Reduction, and Refinement—we advocate for integrating alternative methods when scientifically feasible. We acknowledge that true alternatives to animal models are not yet available due to the complexities of human biology and drug interactions and believe a hybrid model will prove to be the best approach to ensure patient safety for regulated safety testing over the longer term, where appropriate and supported by science. Partner with us to overcome complexity and bring your mAb therapy to patients faster, without compromising quality or compliance.
Frequently Asked Questions (FAQs) About Monoclonal Antibody Testing
-
What is monoclonal antibody (mAb) biologics testing?
Monoclonal antibody testing involves evaluating the purity, potency, stability, and safety of mAbs throughout their development. These tests ensure the therapeutic antibody meets regulatory standards and performs effectively in clinical applications.
-
Why is mAb testing critical for drug development?
mAbs are complex biologics used in the treatment of oncology, autoimmune disorders, and neurodegenerative diseases. Testing is essential to confirm efficacy, immunogenicity, and biosafety, reducing risks during CMC development, clinical trials, and commercialization.
-
Do you offer alternatives to animal-based testing?
Yes. We leverage Next Generation Sequencing (NGS) and innovative in vitro methods to reduce reliance on traditional animal-based assays, accelerating timelines and improving compliance.
